In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...
Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...
Bio-Techne (TECH) reported improved earnings in the latest quarter, up from the loss in the prior quarter. Net profit margins over the trailing twelve-months sit at 6%, down from 14.5% the previous ...
The FDA has granted Breakthrough Device Designation to Bio-Techne's (NASDAQ:TECH) ExoDx Prostate IntelliScore (EPI) test. Breakthrough Device status provides for more intensive guidance on development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback